CLINICAL_TRIALS ClinicalTrials.gov record update

Doxorubicin（A）Plus Camrelizumab(C) Versus Doxorubicin Alone for the First-line Treatment(T) of Select Type of Adcanced Soft Tissue Sarcoma(ACTS): a Randomised Controlled Multi Centers Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04910126
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:09.795525+00:00
Published At: 2021-06-02T00:00:00+00:00
Record Updated At: 2021-06-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Soft Tissue Sarcoma", "Neoplasms, Connective and Soft Tissue", "Sarcoma Metastatic", "Sarcoma,Soft Tissue"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-06-02"
protocolSection.identificationModule.nctId: "NCT04910126"
protocolSection.identificationModule.officialTitle: "Doxorubicin\uff08A\uff09Plus Camrelizumab(C) Versus Doxorubicin Alone for the First-line Treatment(T) of Select Type of Adcanced Soft Tissue Sarcoma(ACTS): a Randomised Controlled Multi Centers Trial"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.